Drug Trial Radar · NCT00443820
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
Last checked: Nov 19, 2026Latest source record: Apr 19, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
526
Actual
Start
Dec 2006
Primary completion
Jun 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Conditions
- Onychomycosis
Interventions
terbinafineDrug
Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
PlaceboDrug
Vehicle (placebo) once daily for 48 weeks
terbinafineDrug
Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
PlaceboDrug
Vehicle (placebo) once daily for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 WeeksTime frame: 52 weeks
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Dr. Fred D. Youngswick
Novato, California
Dr. Larry Doehring
Northglenn, Colorado
Dr. Robert P. Dunne
Melbourne, Florida
Dr. Mark Ling
Newnan, Georgia
Dr. Jesse Plasencia
Chicago, Illinois
Dr. John Mallory
Overland Park, Kansas
Dr. Jeffrey Conrow
Topeka, Kansas
Dr.Michael Kaye
Covington, Louisiana
Dr. Max Weisfeld
Baltimore, Maryland
Dr. Linda Stein-Gold
Detroit, Michigan
Dr. Anna Glaser
St Louis, Missouri
Dr. Richard Scher
New York, New York
Dr. Joseph Jorrizo
Winston-Salem, North Carolina
Dr. Anne Lucky
Cincinnati, Ohio
Dr. Rich Phoebe
Portland, Oregon
Dr. Patricia Westmorland
Simpsonville, South Carolina
Dr. David Horowitz
Nashville, Tennessee
Dr. Jay Lifshen
Irving, Texas
Dr. Richard Pollak
San Antonio, Texas
Dr. Patrick Agnew
Virginia Beach, Virginia
Novartis Investigative Site
Various Cities, France
Novartis
Investigative Site, Germany
Novartis Investigative Site
Various Cities, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.